62 result(s) for 'Lung'
31 - 40 of 62 results for 'Lung'
Sort by
Show
The ERBB2 (or HER2) gene encodes a receptor tyrosine kinase involved in growth factor signaling. Overexpression of this gene is seen in about 20% of invasive breast cancers. ERBB2 gene amplification is a permanent genetic change that results in this continuous overexpression of ERBB2. Trastuzumab (commonly known as Herceptin) has been developed to be effective against ERBB2-positive breast cancer. ERBB2 amplification is also observed in a variety...
The inversion in 2p21 and 2p23 leading to a fusion of the kinase domain of ALK (anaplastic lymphoma kinase) and EML4 (echinoderm microtubule associated protein like 4) has been described in 5-7% of non-small cell lung cancer (NSCLC) cases. Multiple tyrosine kinsae inhibitors (TKI's) specific for ALK have since been approved for first line treatment of NSCLC-patients carrying the fusion gene ALK-EML4. These ALK inhibitors include crizotinib (Xalko...
Antigen Background
Basic calponin (calponin-h1) is a 34 kD protein which exhibits a high degree of homology to acidic and neutral calponins at its N-terminal region. It is an actin, tropomyosin and calmodulin binding protein thought to be involved in the regulation of smooth muscle contraction. The expression of basic calponin is reported to be restricted to smooth muscle cells and is a marker of the differentiated contractile phenotype of develo...
Translocations involving the ROS1 gene at chromosome 6q22 can increase expression of the gene by fusion with SLC34A2 (4p15), but also with other fusion partners. Elevated expression is observed in non-small cell lung cancer (NSCLC). The fusion of ROS1 to the GOPC (FIG) gene, by deletion of a 240 kb DNA fragment, also results in activation of a fusion gene. The ROS1 (6q22) Break probe is optimized to detect translocations involving the ROS1 gene r...
Translocations involving the ROS1 gene at chromosome 6q22 can increase expression of the gene by fusion with SLC34A2 (4p15), but also with other fusion partners. Elevated expression is observed in non-small cell lung cancer (NSCLC), where the success of tyrosine kinase-based therapeutics like Crizotinib (Xalkori) is based on inhibiting the activity of these fusion genes. The fusion of ROS1 to the GOPC (FIG) gene, by deletion of a 240 kb DNA fragm...
Incorporation and Automation of RNAscope Technology into your COVID-19 Viral Pathogenesis Research. Research Use Only, Not for Clinical Diagnostic Procedure
For Research Use Only. Not For Diagnostic Use. Incorporation of the highly sensitive and specific RNAscope technology into your COVID-19 Viral Pathogenesis Research Jyoti Sheldon Applications Research Use Only, Not for Clinical Diagnostic Procedure
Agenda RNAscope technology overview COVID-19 Offerings COVID-19 Publications Research Use Only, Not for Clinical Diagnostic Procedure
RNAscope®In Situ Hybridization (ISH) Technology A hybridization-based signal amplification system with a unique probe design - Simultaneous signal amplification and background suppression Amplification Target-specific binding A specific and sensit...
Slide 1
Welcome
Slide 2
Slide 3
Discuss Pre-Analytics and the impact of improper fixation and artifacts on tissue processing
Discuss Fixation and the impact of incomplete fixation on tissue processing
Describe the impact of improper Prosection
Determine satisfactory Processing of samples
Explain why routine Maintenance is a critical success factor to proper tissue processing
Slide 4
This slide has two examples of what the ideal sections in a perfect world look like under the scope. The skin section on the left is clean looking with the Eosin staining the components of the dermis with different shades. The colon section on the right is crisp with well-defined nuclei and cilia. There is no background staining or muddiness to the stain.
Slide 5
One artifact seen the lab that is n...
It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases
Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects.
Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...
Slide 1
Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson.
Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application.
Slide 2
So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...
The Power of Digital Pathology in Research
1. Leica Biosystems Proprietary Information. For Research Use Only. Not For Use in Diagnostic The Power of Digital Pathology In Research. Caitríona Lyons PhD.
2. Introduction • Caitríona Lyons PhD • Based in Dublin, Ireland • Current Role: • Product Manager Image Analysis, Leica Biosystems • Previous Roles: • Product Owner Image Analysis, Leica Biosystems • Image Analysis Specialist, Leica Biosystems • Education • BSc (Hons) Biomedical Science • PhD Medicine and Health • Postdoc Immunology
3. Agenda • History of Pathology • What is Digital Pathology • Power of Digital Pathology • Leica Biosystems Role in Digital Pathology • The Future of Digital Pathology • Final Thoughts 3 SCAN MANAGE ANALYZE
4. History of Digital Pathology • Patholog...